Ronald Todd Plott, a director of Phio Pharmaceuticals Corp., filed a statement of changes in beneficial ownership on November 10, 2026, reporting a purchase of common stock on November 9, 2026.

Key Highlights

  • Reporting person: Ronald Todd Plott, identified as a Director of Phio Pharmaceuticals Corp.
  • Transaction: Acquisition of 18,300 shares of Common Stock, $0.0001 par value, coded as a purchase (P)
  • Price per share: $0.83
  • Transaction date: November 9, 2026
  • Resulting ownership: 60,300 shares beneficially owned following the transaction, held directly, including shares underlying unvested restricted stock units
  • Issuer and listing: Phio Pharmaceuticals Corp., trading on NASDAQ:PHIO

Director Ronald Todd Plott Adds to Phio Pharmaceuticals Holdings in November 2026

According to the filing, Ronald Todd Plott, a director of Phio Pharmaceuticals Corp., acquired 18,300 shares of the company's Common Stock, $0.0001 par value, on November 9, 2026 at a price of $0.83 per share. The transaction was recorded under transaction code P, indicating an open-market purchase. No derivative securities were reported as part of this filing.

Following the reported transaction, the filing states that Plott beneficially owns a total of 60,300 shares, held directly. The filing includes a footnote noting that this total includes shares of common stock underlying unvested restricted stock units. The ownership form is listed as direct. Phio Pharmaceuticals Corp. is a biopharmaceutical company listed on NASDAQ:PHIO, and the filing was signed by Lisa C. Carson as attorney-in-fact on November 10, 2026.

The filing was submitted individually, with no indication of a joint or group filing by more than one reporting person. There is no notation indicating the transaction was made pursuant to a Rule 10b5-1(c) plan, and no amendment date is provided, indicating this is an original filing.

What Was Disclosed

The filing reports a direct purchase of 18,300 shares of Phio Pharmaceuticals Corp. common stock by Director Ronald Todd Plott at $0.83 per share on November 9, 2026, bringing his total beneficial ownership to 60,300 shares, including unvested restricted stock units.